US equities |
META $623.37 ▼-1.14% TSLA $406.03 ▲+3.68% MU $930.82 ▲+3.00% NVDA $217.98 ▲+0.92% SPCX $149.87 ▲+2.02% AMD $559.01 ▲+5.22% SNDK $1,301.56 ▲+3.66% INTC $93.78 ▲+3.66%
FinancialContent

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.405 +0.125 (+5.48%)
Delayed Quote Updated: 1:20 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
From Rocket Pharmaceuticals, Inc
Via Business Wire
News headline image
5 Analysts Have This to Say About Rocket Pharmaceuticals ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
What 6 Analyst Ratings Have To Say About Rocket Pharmaceuticals ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Rocket Pharmaceuticals ↗
 
Via Benzinga
Where Rocket Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative' ↗
Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases. 
Via Benzinga
News headline image
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Ratings for Rocket Pharmaceuticals ↗
 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention ↗
Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia,... 
Via Benzinga
News headline image
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗
 
Via Benzinga
News headline image
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
News headline image
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
News headline image
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 600 points on Thursday. 
Via Benzinga
News headline image
Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3 ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday. 
Via Benzinga
News headline image
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Completes Acquisition of Renovacor
From Rocket Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket ↗
Gainers Talkspace, Inc. (NASDAQ: TALK) shares rose 48.3% to $0.89 in pre-market trading. Talkspace recently named Jon Cohen as CEO. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >